Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment

被引:1
|
作者
Zhang, Chunlan [1 ]
Wang, Leiming [2 ]
Xu, Caigang [1 ]
Xu, Heng [3 ,4 ,5 ]
Wu, Yu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[2] Ctr Transnatl Med, Shenzhen Bay Lab, Shenzhen, Peoples R China
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Res Ctr Clin Lab Med, Dept Lab Med, Chengdu, Peoples R China
基金
国家重点研发计划;
关键词
immune checkpoint inhibition; the tumor microenvironment; resistance mechanism; lymphoma; metabolites; CLASSICAL HODGKIN LYMPHOMA; CELL LUNG-CANCER; REED-STERNBERG CELLS; PD-1; BLOCKADE; T-CELLS; ACQUIRED-RESISTANCE; ANALYSIS REVEALS; SINGLE-ARM; INDOLEAMINE 2,3-DIOXYGENASE; FOLLICULAR LYMPHOMA;
D O I
10.3389/fphar.2023.1079924
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic strategies of multiple types of malignancies including lymphoma. However, efficiency of ICIs varies dramatically among different lymphoma subtypes, and durable response can only be achieved in a minority of patients, thus requiring unveiling the underlying mechanisms of ICI resistance to optimize the individualized regimens and improve the treatment outcomes. Recently, accumulating evidence has identified potential prognostic factors for ICI therapy, including tumor mutation burden and tumor microenvironment (TME). Given the distinction between solid tumors and hematological malignancies in terms of TME, we here review the clinical updates of ICIs for lymphoma, and focus on the underlying mechanisms for resistance induced by TME, which play important roles in lymphoma and remarkably influence its sensitivity to ICIs. Particularly, we highlight the value of multiple cell populations (e.g., tumor infiltrating lymphocytes, M2 tumor-associated macrophages, and myeloid-derived suppressor cells) and metabolites (e.g., indoleamine 2, 3-dioxygenase and adenosine) in the TME as prognostic biomarkers for ICI response, and also underline additional potential targets in immunotherapy, such as EZH2, LAG-3, TIM-3, adenosine, and PI3Kd/?.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
    Veldman, Johanna
    Visser, Lydia
    van den Berg, Anke
    Diepstra, Arjan
    CANCER TREATMENT REVIEWS, 2020, 82
  • [2] Resistance to immune checkpoint inhibitors and the tumor microenvironment
    Kawashima, Shusuke
    Togashi, Yosuke
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (03) : 240 - 249
  • [3] The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
    Russell, Bonnie L.
    Sooklal, Selisha A.
    Malindisa, Sibusiso T.
    Daka, Lembelani Jonathan
    Ntwasa, Monde
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
    Li, Yaqi
    Liu, Jing
    Gao, Long
    Liu, Yuan
    Meng, Fang
    Li, Xiaoan
    Qin, F. Xiao-Feng
    IMMUNOLOGY LETTERS, 2020, 220 : 88 - 96
  • [5] Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment
    Gajewski, TF
    CLINICAL CANCER RESEARCH, 2006, 12 (07) : 2326S - 2330S
  • [6] The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship
    Sahin, Irem
    Turen, Sevda
    Santapuram, Pranav
    Sahin, Ibrahim Halil
    CANCER DRUG RESISTANCE, 2020, 3 (04) : 699 - 709
  • [7] Priming the tumor microenvironment with epigenetic modifiers to overcome resistance to immune checkpoint inhibitors
    Knox, Tessa J.
    Sahakian, Eva
    Banik, Debarati
    Hadley, Melissa
    Palmer, Erica
    Kim, Jennifer
    Noonepalle, Satish
    Powers, John
    Gracia-Hernandez, Maria
    Oliveira, Vasco
    Cheng, Fengdong
    Chen, Jie
    Barinka, Cyril
    Pinilla-Ibarz, Javier
    Lee, Norman
    Kozikowski, Alan
    Villagra, Alejandro
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Immune Checkpoint Inhibition in Hodgkin Lymphoma
    Moy, Ryan H.
    Younes, Anas
    HEMASPHERE, 2018, 2 (01):
  • [9] Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
    Zhou, Xiaoting
    Ni, Yanghong
    Liang, Xiao
    Lin, Yi
    An, Biao
    He, Xiang
    Zhao, Xia
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
    Zemek, Rachael M.
    Chin, Wee Loong
    Nowak, Anna K.
    Millward, Michael J.
    Lake, Richard A.
    Lesterhuis, W. Joost
    FRONTIERS IN IMMUNOLOGY, 2020, 11